<DOC>
	<DOCNO>NCT00567918</DOCNO>
	<brief_summary>To investigate long-term efficacy safety FK506 ophthalmic suspension patient vernal keratoconjunctivitis</brief_summary>
	<brief_title>Phase III , Long-Term , Open-Label , Extension Study 0.1 % Tacrolimus ( FK506 ) Ophthalmic Suspension Patients With Vernal Keratoconjunctivitis</brief_title>
	<detailed_description>To give chance continuous use 0.1 % FK506 ophthalmic suspension patient vernal keratoconjunctivitis enrol FJ-506D-AC09 study , long-term safety efficacy evaluate . Primary efficacy endpoint mean change baseline ( treatment ) total score objective clinical sign .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Vernal keratoconjunctivitis patient enrol FJ506DAC09 study Patients wish receive continuous administration FK506 ophthalmic suspension Subjects need prohibit concomitant therapy initiation study Subjects need wear contact lenses treatment period test eye Subjects complicate eye infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Keratoconjunctivitis</keyword>
	<keyword>Vernal keratoconjunctivitis</keyword>
	<keyword>FK506</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>